Efficacy of GLP-1RA according to Type 2 Diabetes Phenotypes-A Monocentric Retrospective Study

被引：0
|
作者：
Caruso, Irene
Giordano, Fiorella
Di Gioia, Ludovico
Matichecchia, Immacolata I.
Cignarelli, Angelo
Sorice, Gian Pio
Perrini, Sebastio
Natalicchio, Annalisa
Laviola, Luigi
Giorgino, Francesco
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-783-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
783-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes
    Huang, Tao
    Bosi, Alessandro
    Faucon, Anne-Laure
    Grams, Morgan E.
    Sjolander, Arvid
    Fu, Edouard L.
    Xu, Yang
    Carrero, Juan Jesus
    JAMA INTERNAL MEDICINE, 2024, 184 (10) : 1195 - 1203
  • [32] Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes
    Singhal, Mukul
    Unni, Sudhir
    Schauerhamer, Marisa
    Nguyen, Hiep
    Hurd, Jeff
    McAdam-Marx, Carrie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (03): : 267 - 275
  • [33] GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular-Risk Individuals with Type 2 Diabetes
    Krishnaraj, Aishwarya
    Park, Brady
    Bakbak, Ehab
    Verma, Raj
    Quan, Adrian
    Teoh, Hwee
    Hess, David A.
    Verma, Subodh
    DIABETES, 2024, 73
  • [34] Comparing Healthcare Utilization and Cost in Empagliflozin versus GLP-1RA Initiators with Type 2 Diabetes without Established Cardiovascular Disease
    Htoo, Phyo T.
    Tesfaye, Helen
    DiCesare, Elyse C.
    Wexler, Deborah J.
    Schneeweiss, Sebastian
    Glynn, Robert
    Shay, Christina
    Schmedt, Niklas
    Koeneman, Lisette
    Paik, Julie M.
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 580 - 580
  • [35] Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
    Andreasen, Christine Rode
    Andersen, Andreas
    Knop, Filip Krag
    Vilsboll, Tina
    DIABETES OBESITY & METABOLISM, 2021, 23 : 40 - 52
  • [36] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Hiep Nguyen
    Robert Dufour
    Amanda Caldwell-Tarr
    Advances in Therapy, 2017, 34 : 658 - 673
  • [37] PATIENT PREFERENCES FOR FREQUENCY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) INJECTIONS IN THE TREATMENT OF TYPE 2 DIABETES
    Hauber, A. B.
    Nguyen, H.
    Posner, J.
    Ervin, C. M.
    LaRue, S.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A255 - A255
  • [38] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Nguyen, Hiep
    Dufour, Robert
    Caldwell-Tarr, Amanda
    ADVANCES IN THERAPY, 2017, 34 (03) : 658 - 673
  • [39] Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies
    Chang, Guizhen
    Chen, Baojiang
    Zhang, Litao
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1299 - 1305
  • [40] Invited review. Series: Implications of the recent CVOTs in type 2 diabetes Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano, Angela
    Miccoli, Roberto
    Bianchi, Cristina
    Daniele, Giuseppe
    Del Prato, Stefano
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
12345